Since 1924, Riley Hospital for Children at Indiana University Health has been the only comprehensive children's hospital in the State of Indiana, providing the most advanced care possible for pediatric patients. The Riley Children’s Cancer Center and the Pediatric Hematology/Oncology Faculty at Indiana University School of Medicine are fully integrated as a comprehensive service line with a mission to be a world-class academic healthcare leader for children with cancer and blood disorders.
The Riley Children’s Cancer Center treats 80 percent of all new pediatric cancer diagnoses in Indiana and sees an average of 300 new cancer patients each year. We offer the latest in treatment for all pediatric cancers as well as local access to a variety of investigational treatments under Children’s Oncology Group, Indiana University investigator initiated trials and the Pediatric Precision Genomics Program. The location of Riley Hospital on the IU School of Medicine campus provides a rich environment to enable translational researchers to stretch the limits of current scientific knowledge to promote improvements in child health on both national and international levels. Pediatric faculty research programs have achieved national recognition with an outstanding record for attaining peer-reviewed, external research funding.
The Riley Children’s Cancer Center is the only Children’s Oncology Group center in Indiana that is part of the Phase 1 and Pilot Consortium as well as an overall top 5 accrual site for COG. We are also a member of the Pediatric Brain Tumor Consortium, National Experimental Therapeutics Consortium, the NEXT Consortium and the BMT Clinical Trials Network (BMT-CTN) allowing for early access to clinical trials and newly developed cancer treatments and research. Affiliated with the Melvin and Bren Simon Cancer Center, a designated NCI Cancer Center which also offers clinical trials to young adults through the National Clinical Trials Network. Research by our faculty as well as our nationally and internationally known collaborators led to the first pediatric SPORE ever funded by the NCI. Moreover, our Precision Genomics research led to a NIH programmatic grant aimed at identifying biomarkers that predict the efficacy and toxicity of chemotherapies for children with cancer to optimize treatment of individual pediatric patients. We have a strong foundation in precision medicine which allows doctors and researchers to understand critical individual factors related to the prevention, onset, treatment, progression and health outcomes of pediatric cancer and blood disorders.
The Section of Pediatric Hematology-Oncology at IU School of Medicine is associated with the Herman B Wells Center for Pediatric Research where research faculty is devoted to hematology/oncology investigation in areas such as hematopoiesis, gene transfer, fetal hematopoiesis, molecular biology of gene expression, control of cell proliferation, molecular biology of white blood cell disorders and DNA repair. Research in our collaborative centers focus on both discovery basic research and "translational" studies which seek to rapidly move basic or bench research findings into the clinical setting. The research programs range from studies of fundamental biologic principles utilizing the most sophisticated molecular biologic techniques, to evaluations of new therapeutic strategies, as well as community engagement.
Through research, we provide the latest advances in treating a multitude of pediatric diseases and their complications aimed at optimizing care of children.